An interventional study of Cannabigerol (CBG) in Rheumatoid Arthritis and Inflammatory Disease, sponsored by Raphael Pharma. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by Raphael Pharma · Not applicable, Interventional, and Treatment
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 12 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →This is the only study on the registry with Raphael Pharma as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening for a duration of eight weeks.
Dietary Supplement: Cannabigerol (CBG)
The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
Change in inflammatory markers from Baseline to Week 8
Measurement of blood levels of ESR (Erythrocyte Sedimentation Rate), CRP (C-Reactive Protein), IL6 (Interleukin 6), and TNFa (Tumor Necrosis Factor-alpha) at Baseline, Week 2, Week 4, Week 6, and Week 8.
Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8
Change in self-reported symptoms and quality of life from Baseline to Week 8
Evaluation of participant perceptions of the product's effect on symptoms of rheumatoid arthritis and quality of life using a study-specific questionnaire.
Time frame: Baseline, Week 4, and Week 8
Plan to share: Yes
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.